SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...
Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...
The FDA has granted a “Fast Track” designation to rezpegaldesleukin (REZPEG) as a treatment for severe-to-very severe alopecia areata, according to a press release from the manufacturer, Nektar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results